These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 18950380)

  • 1. Pharmacokinetic interaction between tandospirone and fluvoxamine in the rat contextual conditioned fear stress model and its functional consequence: Involvement of cytochrome P450 3A4.
    Nishikawa H; Inoue T; Masui T; Izumi T; Nakagawa S; Koyama T
    Psychiatry Clin Neurosci; 2008 Oct; 62(5):591-6. PubMed ID: 18950380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of cytochrome P450 (CYP) 3A4 inhibitors on the anxiolytic action of tandospirone in rat contextual conditioned fear.
    Nishikawa H; Inoue T; Masui T; Izumi T; Koyama T
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 May; 31(4):926-31. PubMed ID: 17376576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics and pharmacodynamics of tandospirone in rats exposed to conditioned fear stress.
    Nishitsuji K; To H; Shimizu T; Yanase Y; Yamada T; Hara C; Mine K; Higuchi S
    Eur Neuropsychopharmacol; 2006 Jul; 16(5):376-82. PubMed ID: 16406508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effects of tandospirone and selective serotonin reuptake inhibitors on the contextual conditioned fear stress response in rats.
    Nishikawa H; Inoue T; Izumi T; Koyama T
    Eur Neuropsychopharmacol; 2007 Oct; 17(10):643-50. PubMed ID: 17368862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Facilitation of fear extinction by the 5-HT(1A) receptor agonist tandospirone: possible involvement of dopaminergic modulation.
    Saito Y; Matsumoto M; Yanagawa Y; Hiraide S; Inoue S; Kubo Y; Shimamura K; Togashi H
    Synapse; 2013 Apr; 67(4):161-70. PubMed ID: 23152167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of AP521, a novel anxiolytic drug, in three anxiety models and on serotonergic neural transmission in rats.
    Kasahara K; Hashimoto S; Hattori T; Kawasaki K; Tsujita R; Nakazono O; Takao K; Kawakubo H; Nagatani T
    J Pharmacol Sci; 2015 Jan; 127(1):109-16. PubMed ID: 25704026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic treatment with tandospirone, a serotonin 1A receptor partial agonist, inhibits psychosocial stress-induced changes in hippocampal neurogenesis and behavior.
    Murata Y; Yanagihara Y; Mori M; Mine K; Enjoji M
    J Affect Disord; 2015 Jul; 180():1-9. PubMed ID: 25879718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tandospirone stimulates prolactin secretion in the rat by an action at serotonin-1A receptors.
    Mulroney SE; Skudlarek C; Shemer A; Lumpkin MD; Kellar KJ
    J Pharmacol Exp Ther; 1994 Feb; 268(2):862-7. PubMed ID: 8113999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of CYP3A4 as the primary cytochrome P450 responsible for the metabolism of tandospirone by human liver microsomes.
    Natsui K; Mizuno Y; Tani N; Yabuki M; Komuro S
    Eur J Drug Metab Pharmacokinet; 2007; 32(4):233-40. PubMed ID: 18348473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yokukansan, a traditional Japanese herbal medicine, enhances the anxiolytic effect of fluvoxamine and reduces cortical 5-HT
    Ohno R; Miyagishi H; Tsuji M; Saito A; Miyagawa K; Kurokawa K; Takeda H
    J Ethnopharmacol; 2018 Apr; 216():89-96. PubMed ID: 29382554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticonflict action of tandospirone in a modified Geller-Seifter conflict test in rats.
    Shimizu H; Kumasaka Y; Tanaka H; Hirose A; Nakamura M
    Jpn J Pharmacol; 1992 Mar; 58(3):283-9. PubMed ID: 1355147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of tandospirone (SM-3997) interactions with neurotransmitter receptor binding sites.
    Hamik A; Oksenberg D; Fischette C; Peroutka SJ
    Biol Psychiatry; 1990 Jul; 28(2):99-109. PubMed ID: 1974152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics, brain uptake, and receptor binding of tandospirone and its metabolite 1-(2-pyrimidinyl)-piperazine.
    Miller LG; Thompson ML; Byrnes JJ; Greenblatt DJ; Shemer A
    J Clin Psychopharmacol; 1992 Oct; 12(5):341-5. PubMed ID: 1362206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of chronic administration of flesinoxan and fluvoxamine on freezing behavior induced by conditioned fear.
    Li XB; Inoue T; Hashimoto S; Koyama T
    Eur J Pharmacol; 2001 Aug; 425(1):43-50. PubMed ID: 11672573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the anxiolytic-like effects of fluvoxamine, milnacipran and risperidone in mice using the conditioned fear stress paradigm.
    Miyamoto J; Tsuji M; Takeda H; Ohzeki M; Nawa H; Matsumiya T
    Eur J Pharmacol; 2004 Nov; 504(1-2):97-103. PubMed ID: 15507225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tandospirone suppresses impulsive action by possible blockade of the 5-HT1A receptor.
    Ohmura Y; Kumamoto H; Tsutsui-Kimura I; Minami M; Izumi T; Yoshida T; Yoshioka M
    J Pharmacol Sci; 2013; 122(2):84-92. PubMed ID: 23707971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of tandospirone on second messenger systems and neurotransmitter release in the rat brain.
    Tanaka H; Tatsuno T; Shimizu H; Hirose A; Kumasaka Y; Nakamura M
    Gen Pharmacol; 1995 Dec; 26(8):1765-72. PubMed ID: 8745167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5-HT1A agonists disrupt memory of fear conditioning in mice.
    Quartermain D; Clemente J; Shemer A
    Biol Psychiatry; 1993 Feb; 33(4):247-54. PubMed ID: 8471677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A new approach to innovating selective anxiolytics: pharmacological profile of a novel 5-HT1A agonist (tandospirone)].
    Sasa M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1997 Apr; 17(2):53-9. PubMed ID: 9201724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of tandospirone on sleep latency in rats placed on a grid suspended over water.
    Utsu Y; Shinomiya K; Tokunaga S; Ohmori A; Kamei C
    J Pharmacol Sci; 2007 Sep; 105(1):112-6. PubMed ID: 17827866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.